[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Hvivo Plc (HVO.LN)

Hvivo Plc (HVO.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Hvivo Plc 40 Bank Street Floor 24 London E14 5NR GBR

https://www.hvivo.com P: 207-756-1300

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

hVIVO PLC is a full-service early phase Contract Research Organisation (CRO). It delivers end-to-end clinical development services to a diverse and expanding client base. The group specialises in conducting human challenge trials across multiple infectious and respiratory indications. It also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its subsidiary, it provides early-phase clinical trial services and Early Drug Development Consulting and Biometry services to the biopharma sector. It provides development solutions from preclinical stages through Phase II trials, via FluCamp. Geographically, the company generates maximum revenue from Europe, followed by North America, the United Kingdom, and Asia.

Key Statistics

Overview:

Market Capitalization, $K 58,170
Shares Outstanding, K 688,401
% of Insider Shareholders 4.95%
% of Institutional Shareholders 11.79%

Financials:

Annual Sales, $ 46,773 K
Annual Net Income, $ -5,993 K

Growth:

1-Year Return -25.41%
3-Year Return -46.09%
5-Year Return 0.00%
5-Year Revenue Growth 17.82%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.01
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Most Recent Dividend 0.002 on 05/15/25
Next Ex-Dividends Date 05/15/25
Dividend Payable Date 06/11/25
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 12/14/12

HVO.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -14.47%
Return-on-Assets % -7.46%
Profit Margin % -12.81%
Debt/Equity 0.32
Price/Sales 1.24
Price/Book 1.52
Book Value/Share 0.06
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.